Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas.

Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C, Lowe SW.

Nature. 2007 Feb 8;445(7128):656-60. Epub 2007 Jan 24. Erratum in: Nature. 2011 May 26;473(7348):544.

2.

Restoration of p53 function: a new therapeutic strategy to induce tumor regression?

Beraza N, Trautwein C.

Hepatology. 2007 Jun;45(6):1578-9.

PMID:
17538933
4.

CKI╬▒ ablation highlights a critical role for p53 in invasiveness control.

Elyada E, Pribluda A, Goldstein RE, Morgenstern Y, Brachya G, Cojocaru G, Snir-Alkalay I, Burstain I, Haffner-Krausz R, Jung S, Wiener Z, Alitalo K, Oren M, Pikarsky E, Ben-Neriah Y.

Nature. 2011 Feb 17;470(7334):409-13. doi: 10.1038/nature09673.

PMID:
21331045
5.

Restoration of p53 function leads to tumour regression in vivo.

Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R, Jacks T.

Nature. 2007 Feb 8;445(7128):661-5. Epub 2007 Jan 24.

PMID:
17251932
6.

An RNA interference screen for identifying downstream effectors of the p53 and pRB tumour suppressor pathways involved in senescence.

Rovillain E, Mansfield L, Lord CJ, Ashworth A, Jat PS.

BMC Genomics. 2011 Jul 8;12:355. doi: 10.1186/1471-2164-12-355.

7.

UBTD1 induces cellular senescence through an UBTD1-Mdm2/p53 positive feedback loop.

Zhang XW, Wang XF, Ni SJ, Qin W, Zhao LQ, Hua RX, Lu YW, Li J, Dimri GP, Guo WJ.

J Pathol. 2015 Mar;235(4):656-67. doi: 10.1002/path.4478. Epub 2015 Jan 7.

PMID:
25382750
8.

Activation of p53 by oncogenes.

Lowe SW.

Endocr Relat Cancer. 1999 Mar;6(1):45-8. Review.

9.

Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis.

Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, Koutcher JA, Scher HI, Ludwig T, Gerald W, Cordon-Cardo C, Pandolfi PP.

Nature. 2005 Aug 4;436(7051):725-30.

10.

Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence.

Kortlever RM, Higgins PJ, Bernards R.

Nat Cell Biol. 2006 Aug;8(8):877-84. Epub 2006 Jul 23.

11.

Proteomic Analysis Reveals GMP Synthetase as p53 Repression Target in Liver Cancer.

Holzer K, Drucker E, Roessler S, Dauch D, Heinzmann F, Waldburger N, Eiteneuer EM, Herpel E, Breuhahn K, Zender L, Schirmacher P, Ori A, Singer S.

Am J Pathol. 2017 Feb;187(2):228-235. doi: 10.1016/j.ajpath.2016.09.022. Epub 2016 Dec 7.

PMID:
27939741
12.

p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa.

Valente LJ, Gray DH, Michalak EM, Pinon-Hofbauer J, Egle A, Scott CL, Janic A, Strasser A.

Cell Rep. 2013 May 30;3(5):1339-45. doi: 10.1016/j.celrep.2013.04.012. Epub 2013 May 9.

13.

The role of DNA damage responses in p53 biology.

Speidel D.

Arch Toxicol. 2015 Apr;89(4):501-17. doi: 10.1007/s00204-015-1459-z. Epub 2015 Jan 25. Review.

PMID:
25618545
14.

Tumour suppression by p53: the importance of apoptosis and cellular senescence.

Zuckerman V, Wolyniec K, Sionov RV, Haupt S, Haupt Y.

J Pathol. 2009 Sep;219(1):3-15. doi: 10.1002/path.2584. Review.

PMID:
19562738
15.

Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence.

Lin HK, Chen Z, Wang G, Nardella C, Lee SW, Chan CH, Yang WL, Wang J, Egia A, Nakayama KI, Cordon-Cardo C, Teruya-Feldstein J, Pandolfi PP.

Nature. 2010 Mar 18;464(7287):374-9. doi: 10.1038/nature08815. Erratum in: Nature. 2010 Jul 15;466(7304):398. Chan, Chan-Hsin [corrected to Chan, Chia-Hsin].

16.

Combination therapy with PEG-IFN-alpha and 5-FU inhibits HepG2 tumour cell growth in nude mice by apoptosis of p53.

Hagiwara S, Kudo M, Nakatani T, Sakaguchi Y, Nagashima M, Fukuta N, Kimura M, Hayakawa S, Munakata H.

Br J Cancer. 2007 Dec 3;97(11):1532-7. Epub 2007 Oct 30.

17.

Reciprocal regulation of p53 and malic enzymes modulates metabolism and senescence.

Jiang P, Du W, Mancuso A, Wellen KE, Yang X.

Nature. 2013 Jan 31;493(7434):689-93. doi: 10.1038/nature11776. Epub 2013 Jan 13.

18.

Pharmacologic p53 activation blocks cell cycle progression but fails to induce senescence in epithelial cancer cells.

Huang B, Deo D, Xia M, Vassilev LT.

Mol Cancer Res. 2009 Sep;7(9):1497-509. doi: 10.1158/1541-7786.MCR-09-0144. Epub 2009 Sep 8.

19.

Ku80 functions as a tumor suppressor in hepatocellular carcinoma by inducing S-phase arrest through a p53-dependent pathway.

Wei S, Xiong M, Zhan DQ, Liang BY, Wang YY, Gutmann DH, Huang ZY, Chen XP.

Carcinogenesis. 2012 Mar;33(3):538-47. doi: 10.1093/carcin/bgr319. Epub 2012 Jan 5.

PMID:
22226916
20.

Senescence surveillance of pre-malignant hepatocytes limits liver cancer development.

Kang TW, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D, Hohmeyer A, Gereke M, Rudalska R, Potapova A, Iken M, Vucur M, Weiss S, Heikenwalder M, Khan S, Gil J, Bruder D, Manns M, Schirmacher P, Tacke F, Ott M, Luedde T, Longerich T, Kubicka S, Zender L.

Nature. 2011 Nov 9;479(7374):547-51. doi: 10.1038/nature10599.

PMID:
22080947

Supplemental Content

Support Center